Humacyte, INC 10-Q quarterly reports

Humacyte, Inc. reported a significant reduction in net loss and its first product revenue from Symvess sales, while navigating increased cash burn and multiple legal proceedings.

Humacyte reports initial Symvess product revenue and reduced operating losses in Q2 2025, alongside strategic cost reductions and ongoing clinical trial progress, despite a denied NTAP application and persistent legal challenges.

Humacyte, Inc. reports its first quarter 2025 financial results, highlighted by the commencement of the commercial launch of its ATEV product, Symvess, for vascular trauma.

Humacyte's Q3 2024 results reveal increased operating losses and a going concern warning due to delayed FDA review and the need for additional capital.

Humacyte's Q2 2024 results show increased operating losses and a net loss, alongside concerns about the company's ability to continue as a going concern due to delayed FDA review and funding requirements.

Humacyte's Q1 2024 results show increased R&D spending and a net loss, alongside a successful public offering and a revenue interest purchase agreement installment.